Search Results
Sep 10, 2026, 07:00 ET Carlyle, Insight Partners, and JMI Equity Unveil Exiger's Complete AI-Built Transformation
future."The AI-PDLC automates each stage of development with AI now writing 95% of first-generation code and seamlessly integrates with Exiger's secure CI/CD pipeline on top of the world's largest proprietary dataset in supply chain, defense, and corporate intelligence. It has radically improved the speed,
More news about: Exiger
Sep 10, 2026, 07:00 ET Carlyle, Insight Partners, and JMI Equity Unveil Exiger's Complete AI-Built Transformation
future."The AI-PDLC automates each stage of development with AI now writing 95% of first-generation code and seamlessly integrates with Exiger's secure CI/CD pipeline on top of the world's largest proprietary dataset in supply chain, defense, and corporate intelligence. It has radically improved the speed,
More news about: Exiger
Sep 10, 2026, 03:00 ET Taiyo Holdings Launches Next-generation Semiconductor-packaging Material "FPIM Series," Achieving Its First Three-layer RDL Formation with 700-nm CD on 12-inch Wafers
structure with a CD (*4) of 1.6 micrometers on 12-inch wafers.In this research, a three-layer RDL structure was formed on 12-inch wafers using the Material and evaluated. As a result, the target dimension of 700-nm CD was achieved for both interconnects and vias. The 700-nm CD metal 1 layer (M1)
More news about: Taiyo Holdings Co. Ltd.
Sep 09, 2026, 11:02 ET Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
divergent clinical outcomes. Their analysis independently identified PLA2G2D as a top hit in the dendritic cell and macrophage populations interacting with CD8+ T cells in patients with worse outcomes.A mechanism the field had overlooked. Beyond identifying the target, the Apeximmune team uncovered
More news about: Apeximmune
Sep 09, 2026, 08:00 ET UCB receives U.S. FDA Breakthrough Therapy Designation for CIMZIA®(certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)
CIMZIA is a tumor necrosis factor (TNF) blocker indicated for:Reducing signs and symptoms of Crohn's disease (CD) and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapyTreatment
More news about: UCB
Sep 09, 2026, 06:00 ET HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit
align."A Potential First for the SIRPα-Fc Fusion Protein ClassWhile Expanded Access pathways have previously been utilized for the anti-CD47 monoclonal antibody, HCB101-EA-001 is clinically and structurally distinct:Targeted Continuation: Unlike broad population access programs, HCB101-EA-001
More news about: HanchorBio Inc.
Sep 09, 2026, 04:21 ET Qedma and HQC2 Demonstrate Unprecedented Accuracy in Quantum Chemistry on Quantum Computers
software package, which enables the calculation of ground- and excited-state energies as well as molecular spectroscopic properties, including UV/Vis, CD and NMR spin-spin coupling constants, on quantum computing platforms.Qedma Media Contact:Diane McKayeSi14 Global Communications
More news about: Qedma
Sep 09, 2026, 04:00 ET Giovanni Caforio Appointed Operating Advisor to CD&R Funds
2026 /PRNewswire/ -- CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating
More news about: CD&R
Sep 09, 2026, 04:00 ET Giovanni Caforio Appointed Operating Advisor to CD&R Funds
2026 /PRNewswire/ -- CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating
More news about: CD&R
Sep 08, 2026, 10:37 ET Certificate Authority Market to Reach USD 397.14 Mn by 2031 with Cloud Deployment Capturing 57.83% of Revenue, Says Mordor Intelligence
manual management increasingly difficult. Enterprises are therefore adopting automated certificate lifecycle platforms integrated with DevSecOps and CI/CD pipelines to monitor inventories, trigger renewals, and distribute certificates across growing cloud, application, API, and microservice environments.
More news about: Mordor Intelligence Private Limited
Sep 08, 2026, 10:34 ET PeproMene Bioは、再発・難治性B細胞リンパ腫において、CD19 CAR T細胞療法の事前治療が失敗した場合を含め、深く持続的な完全寛解が認められた画期的な第1相臨床試験の結果が『The Lancet』誌に掲載されたことを発表
Hopeは、患者の登録に加え、調整センターおよび製造拠点として、今後もこの臨床試験を支援し続けていきます。」2024年12月、Institute for Follicular Lymphoma Innovation (IFLI)は、再発または難治性の濾胞性リンパ腫患者を対象としたPMB-CT01の臨床開発を支援するため、最大1,100万ドルを拠出することを決定しています。「CD19を標的としたCAR T細胞療法を受けた後にリンパ腫が再発した患者にとって、新たな標的は新たな希望につながる可能性があります。IFLIは、PeproMene BioがBAFF-R CAR T細胞療法の開発を推進することを支援できることを誇りに思うとともに、こうした初期段階における持続的な奏効に勇気づけられています」と、Institute
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 09:00 ET IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
with or without durvalumab in patients with ES-SCLC; DeLLphi-311, a Phase 1b study of tarlatamab in combination with etakafusp alfa (AB248), a novel CD8+ T-cell selective interleukin-2 (IL-2), in patients with ES-SCLC; DeLLphi-312, a randomized Phase 3 study evaluating tarlatamab in combination with
More news about: Amgen
Sep 08, 2026, 08:00 ET Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
European customers' needs. IONIQ 3's Aero Hatch typology has been created to deliver class-leading efficiency and range, with a drag coefficient of 0.263 Cd and up to 497 km of range (WLTP). With 441 liters of trunk volume, best-in-class interior space, a segment-leading 14.6-inch display featuring Hyundai's
More news about: Hyundai Motor Company
Sep 08, 2026, 07:30 ET Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
www.inhibrx.com.About INBRX-106 INBRX-106 is a hexavalent agonist targeting OX40 (CD134), a costimulatory receptor on T-cells. Utilizing Inhibrx's proprietary single-domain antibody (sdAb) platform, INBRX-106 is designed to achieve the
More news about: Inhibrx Biosciences, Inc.
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
diseases where B-cell depletion is already proven.""These early results are encouraging, particularly for patients whose disease progressed after CD19 or CD20-directed T-cell therapy," said Stephen Forman, M.D., paper co-author and director of the Hematologic Malignancies Institute at City of Hope. "City
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio Announces Publication in The Lancet of Breakthrough Phase 1 Clinical Trial Results Demonstrating Deep and Durable Complete Responses in Relapsed/Refractory B-cell Lymphomas, including after prior CD19 CAR T-cell failure
diseases where B-cell depletion is already proven.""These early results are encouraging, particularly for patients whose disease progressed after CD19 or CD20-directed T-cell therapy," said Stephen Forman, M.D., paper co-author and director of the Hematologic Malignancies Institute at City of Hope. "City
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET 페프로민 바이오, 기존 CD19 CAR T세포 치료 실패 포함 재발성/불응성 B세포 림프종에서 깊고 지속적인 완전관해 입증한 제1상 임상시험 결과 랜싯에 게재 발표
새로운 가능성을 열 수 있다"고 덧붙였다.공동 저자이자 시티 오브 호프 혈액악성종양연구소(Hematologic Malignancies Institute) 소장인 스티븐 포먼(Stephen Forman) 의학박사는 "이번 초기 결과는 고무적이며, 특히 CD19 또는 CD20 표적 T세포 치료 후 질환이 진행된 환자들에게 의미가 크다. 시티 오브 호프는 환자 등록과 더불어 임상시험 조정 센터 및 제조 기관으로서 이번 시험을 계속 지원할 것이다"라고 말했다.2024년 12월 여포성 림프종 혁신 연구소(Institute
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio anuncia la publicación en The Lancet de los resultados de su ensayo clínico de fase 1
eficacia"."Estos primeros resultados son alentadores, especialmente para los pacientes cuya enfermedad progresó tras la terapia con células T dirigidas a CD19 o CD20", afirmó el Dr. Stephen Forman, coautor del artículo y director del Instituto de Neoplasias Hematológicas de City of Hope. "City of Hope seguirá apoyando
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio gibt die Veröffentlichung bahnbrechender Ergebnisse einer klinischen Phase-1-Studie in The Lancet bekannt, die tiefe und anhaltende vollständige Remissionen bei rezidivierten/refraktären B-Zell-Lymphomen belegen, auch nach vorherigem Versagen einer CD19-CAR-T-Zell-Therapie
B-Zell-Depletion bereits bewährt hat."„Diese ersten Ergebnisse sind vielversprechend, insbesondere für Patienten, deren Erkrankung nach einer gegen CD19 oder CD20 gerichteten T-Zell-Therapie fortgeschritten ist", sagte Stephen Forman, M.D., Mitautor der Veröffentlichung und Direktor des Hematologic Malignancies
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 08, 2026, 06:01 ET PeproMene Bio annonce la publication dans The Lancet des résultats d'un essai clinique de phase 1 démontrant des réponses complètes profondes et durables dans les lymphomes à cellules B récidivants ou réfractaires, y compris après l'échec d'un traitement par cellules CAR-T ciblant le CD19
résultats sont encourageants, en particulier pour les patients dont la maladie a évolué après un traitement par lymphocytes T ciblant les marqueurs CD19 ou CD20 », déclare le Dr Stephen Forman, coauteur de l'article et directeur de l'Hematologic Malignancies Institute du City of Hope. « Le City of Hope
More news about: PeproMene Bio, Inc.; Institute for Follicular Lymphoma Innovation (IFLI)
Sep 07, 2026, 22:26 ET IRON, the World's First Advanced General-Purpose Humanoid Robot, Walks off the Production Lines as XPENG's Humanoid Robot Manufacturing Facility Is Officially Commissioned
https://wetransfer.com/downloads/64c97a585428373656af84cd175c55e820260908011306/cf28c8fe399b5db33258de769e27cca220260908011306/5cd228XPENG's robot production lines are the world's first automated
More news about: XPeng Inc.
Sep 07, 2026, 21:00 ET CNCF Welcomes New Silver Members as Enterprises Scale AI From Training to Inference
world's legal work: collaborative AI for exceptional lawyers. Legora's multi-region AI platform runs on Kubernetes and the CNCF ecosystem, including Argo CD, Kargo, Crossplane, Cilium, and Kyverno. With engineering offices in Stockholm, New York, and London, the company is growing its platform and infrastructure
More news about: Cloud Native Computing Foundation
Sep 07, 2026, 06:59 ET SunTec India Introduces AI-Accelerated Digital Engineering, Integrating AI Across the Software Development Lifecycle
minimizing post-deployment bugs.Optimized DevOps Pipeline: Automated build validation, predictive infrastructure monitoring, and seamless CI/CD integration.Human-in-the-Loop Governance: Enterprise-grade security protocols, architectural oversight, and subject-matter-expert code
More news about: SunTec India
Sep 07, 2026, 01:00 ET Hyundai Motor Company Becomes Official Automotive Partner of the UEFA Champions League
European customers' needs. IONIQ 3's Aero Hatch typology has been created to deliver class-leading efficiency and range, with a drag coefficient of 0.263 Cd and up to 497 km of range (WLTP). With 441 liters of trunk volume, best-in-class interior space, a segment-leading 14.6-inch display featuring Hyundai's
More news about: Hyundai Motor Company
Sep 06, 2026, 20:01 ET Harbour BioMed Successfully Included in the Stock Connect, Reinforcing Capital Market Recognition
Bio; an ex-China licensing agreement for HBM7020 (BCMA×CD3) with Otsuka Pharmaceutical; a license agreement and equity partnership with Solstice Oncology for HBM4003; and a licensing and collaboration agreement with AstraZeneca for HBM7022 (Claudin18.2×CD3). These partnerships strongly demonstrate the Company's
More news about: Harbour BioMed